<DOC>
	<DOCNO>NCT01326481</DOCNO>
	<brief_summary>The purpose study determine recommend phase 2 dose overall safety tolerability TRC105 give combination capecitabine treatment patient progressive recurrent metastatic breast cancer .</brief_summary>
	<brief_title>Open Label Dose-Finding Study TRC105 Plus Capecitabine Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically proven advanced solid cancer curative therapy available ( Part 1 ) Histologically prove metastatic Her2negative breast cancer ( Part 2 ) Measurable disease RECIST 1.1 criterion ( Part 2 ) Willing able consent self participate study Progressive recurrent disease prior systemic chemotherapy regimen Age ≥ 18 year ECOG performance status 0 1 Resolution acute toxic effect prior therapy NCI CTCAE Grade ≤ 1 baseline ( except alopecia ) Adequate organ function Prior treatment one systemic chemotherapy regimen metastatic disease . Prior treatment TRC105 History hypersensitivity reaction antimetabolite therapy Receipt investigational agent within 28 day start study treatment Prior surgery ( include open biopsy ) , radiation therapy systemic therapy within 28 day start study treatment Minor surgical procedure within 14 day prior first dose TRC105 History brain metastasis , spinal cord compression , carcinomatous meningitis , new evidence brain leptomeningeal disease Angina , MI , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack , arterial embolism , pulmonary embolism , DVT , PTCA CABG within past 6 month Uncontrolled chronic hypertension define systolic &gt; 140 diastolic &gt; 90 despite optimal therapy Past medical history acquire inherited coagulopathy include patient know hereditary hemorrhagic telangiectasia Thrombolytic anticoagulant use ( except maintain i.v . catheter ) within 10 day prior first dose TRC105 Cardiac dysrhythmias NCI CTCAE Grade ≥ 2 within last month Hemorrhage within 28 day start study treatment Unhealed wound within 28 day start study treatment History peptic ulcer disease gastritis within past 6 month , unless treat condition complete resolution document esophagogastroduodenoscopy ( EGD ) within 28 day start study treatment Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness Known active viral nonviral hepatitis History hypersensitivity reaction human mouse antibody product Lung cancer central chest lesion Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>TRC105</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>CD105</keyword>
	<keyword>Endoglin</keyword>
	<keyword>TRACON Pharma</keyword>
	<keyword>Roswell Park Cancer Institute</keyword>
	<keyword>Department Defense</keyword>
</DOC>